Instinct Bio Technical Company Holdings Inc. Ordinary Shares(BIOT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.19
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BIOT

11/13/2026: BIOT (1-star) is currently NOT-A-BUY. Pass it for now.

Instinct Bio Technical Company Holdings Inc. is a micro-cap vertically integrated holding company focused on stem cell research, regenerative wellness, and advanced skincare products. The company benefits from a structured approach linking R&D to international clinic and product distribution initiatives, notably expanding into Southeast Asia. Its primary investment story rests on capturing high-margin growth within the burgeoning longevity and aesthetic health markets. However, it faces intense competition, early-stage financial losses, high share price volatility, and execution risks. The stock suits speculative growth investors willing to monitor foreign clinic rollouts and cash burn trends closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitWhile operating in a growth sector, the company lacks the consistent revenue scaling required for a standard growth profile.
Momentum investorWeak fitThe stock trades at depressed levels following its IPO decline, offering a weak fit unless a strong technical upturn signal emerges.
Value investorWeak fitUnproven earnings and negative net income make traditional fundamental value assessment difficult.
Dividend investorWeak fitThe company pays no dividends, making it entirely unsuitable for income-focused investors.
Low-risk investorWeak fitHigh share price volatility and micro-cap status present substantial risks incompatible with capital preservation strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap status and low liquidity drive severe daily price swings.
Valuation riskHighLack of stable earnings makes fundamental price support difficult to gauge.
Competition risk (aesthetic and wellness competition)HighThe company competes against massive, well-established beauty and medical conglomerates.
Business qualityMediumVertically integrated operations offer long-term potential but are still in early validation phases.
Dividend incomeLow / noneNo cash distribution is provided to shareholders.
Execution riskHighSuccess relies entirely on executing foreign clinic expansions and new product rollouts.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.47M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 380.8K shares
Beta -
52 Weeks Range 0.17 - 50.00
Updated Date 11/15/2026
52 Weeks Range 0.17 - 50.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.01

Sector & Industry Intelligence

Sector

Consumer Defensive

Defensive
Sentiment
Correction Expected
Momentum
BUY Breadth Improving
BUY participation
95.0%
Active BUY / eligible
19 / 20
30-Day BUY Count Change
+13
Market state
Correction Expected

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Household & Personal Products

BUY participation
100.0%
Active BUY / eligible
2 / 2
30-Day BUY Count Change
+1

Eligible universe: 2 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Insufficient Data
PRICE PATH

Insufficient Data

The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
PRICE STABILITY

Insufficient Data

The stock price exhibits a Insufficient Data stability pattern.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BIOT receives a 3-star rating based on the available scored pillars. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
BIOT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2024 versus FY2023, strong cash generation (FCF margin 20.4%) is partially offset by negative earnings growth (-86.3%), negative revenue growth (-19.6%), soft profitability (net margin 2.7%).

Financial Health Rating

★★★★★
BIOT's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 37.1%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is BIOT's strongest growth driver at +153.7% FY2024 versus FY2023 (strong, 5 stars). By comparison, while revenue growth (-19.6%, negative) and earnings growth (-86.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 6.1% (soft) and 0.0% of outstanding shares are publicly tradable (soft). Insider ownership of 12.19% supports management-shareholder alignment.

Unit Economics (Per $1K Revenue)

★★★★★
BIOT generates approximately $724 of gross profit, $-25 of operating income, and $204 of free cash flow for every $1,000 of revenue. Based on FY2024 results. Weak margins and strong cash conversion support a 3-star rating, while capital efficiency is weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 40.96%

Quantitative Style Profile

★★★★★
BIOT has a relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Regenerative Skincare ProductsSales of stem cell-derived cosmetic and dermatological topical formulations.Product sales form the baseline consumer goods revenue pillar.
Clinic and Wellness ServicesSubscription-based wellness and aesthetic treatments offered through specialized clinic locations.Recurring service subscription fees aim to build predictable health-service revenue.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5.62M
Price to Sales(TTM) 5.02
Enterprise Value 5.62M
Price to Sales(TTM) 5.02
Enterprise Value to Revenue 5.15
Enterprise Value to EBITDA -
Shares Outstanding 28.79M
Shares Floating -
Shares Outstanding 28.79M
Shares Floating -
Percent Insiders 12.19
Percent Institutions 6.13

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.